| Cat.No. | Name | Information |
|---|---|---|
| M2315 | Necrostatin-1 | Necrostatin-1 (NEC-1) is a potent inhibitor of necroptosis, with an EC50 of 490 nM in Jurkat cells. Necrostin-1 is the first identified RIPK1 inhibitor, EC50=182 nM, that reduces inflammation and inhibits colitis associated tumorigenesis. Necrostatin-1 (Nec-1) is also an inhibitor of IDO. |
| M8951 | WEHI-345 | WEHI-345 is a potent and selective RIPK2 inhibitor with IC50 of 0.13 μM. WEHI-345 delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation. |
| M9074 | GSK872 | GSK872 is a receptor interacting protein kinase-3 (RIP3) inhibitor, which inhibits kinase activity with an IC50 of 1.3 nM. |
| M10602 | Necrostatin 2 racemate | Necrostatin-2 racemate (also known as 7-Cl-O-Nec-1 and Nec-1s) is a potent and specific receptor-interacting protein kinase 1 (RIPK1) inhibitor lacking the IDO-targeting effect, with >1000-fold more selective for RIPK1 than for any other kinase out of 485 human kinases. |
| M41366 | Zharp2-1 | Zharp2-1 is an oral effective RIPK2 inhibitor, highly associated with inflammatory bowel disease (IBD). |
| M41365 | RIPK2/3-IN-1 | RIPK2/3-IN-1 is a potent dual RIPK2/3 kinases inhibitor with IC50 values of 3 nM and 117 nM, respectively. |
| M41364 | RIP1 kinase inhibitor 7 | RIP1 kinase inhibitor 7 is a potent receptor interacting protein 1 kinase (RIP1) Inhibitor with an IC50 of <100 nM for human RIP1. |
| M41363 | RIP1 kinase inhibitor 5 | RIP1 kinase inhibitor 5 is a potent inhibitor of RIP1, which is used as a checkpoint kinase to control tumor immunity. |
| M41358 | RIP1 kinase inhibitor 8 | RIP1 kinase inhibitor 8 is a potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitor with an IC50 of 20 nM. |
| M29760 | RIPK3-IN-2 | RIPK3-IN-2 is a RIP3 inhibitor. RIPK3-IN-2 can be used in diseases caused by or associate with activated necrotic pathways research. |
| M29640 | GNE684 | GNE684 is an orally active, potent receptor-interacting protein 1 (RIP1) inhibitor with Kiapp values of 21 nM, 189 nM, and 691 nM for human, mouse, and rat RIP1, respectively, and can be used in studies related to acute graft-versus-host disease (aGVHD). |
| M29536 | cRIPGBM chloride | cRIPGBM chloride, an orally active, proapoptotic derivative. cRIPGBM can be generated from glioblastoma multiforme (GBM) cancer stem cells (CSCs). cRIPGBM(chloride) targets to receptor-interacting protein kinase 2 (RIPK2) to induce caspase 1-dependent apoptosis. cRIPGBM(chloride) suppresses the formation of RIPK2/TAK1 (prosurvival complex), and increases the formation of RIPK2/caspase 1 (proapoptotic complex). cRIPGBM(chloride) exerts potent anti-tumor activity in vivo in animal models. |
| M29535 | cRIPGBM | cRIPGBM, a proapoptotic derivative of RIPGBM, a cell type-selective inducer of apoptosis in GBM cancer stem cells (CSCs) by binding to receptor-interacting protein kinase 2 (RIPK2), with an EC50 of 68 nM in GBM-1 cells. |
| M29295 | RIPK-IN-4 | RIPK-IN-4 is a potent and selective RIPK2 inhibitor with excellent oral bioavailability, and has an IC50 of 3 nM. |
| M28745 | OD36 | OD36 is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with KDs of 37 nM. |
| M28626 | RIP2 kinase inhibitor 2 | RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor. |
| M28393 | GSK2983559 active metabolite | GSK2983559 active metabolite is an active metabolite of GSK2983559. GSK2983559 active metabolite is a receptor interacting protein-2 (RIP2) kinase inhibitor. |
| M21566 | RIPK1-IN-4 | RIPK1-IN-4 is a potent type II kinase receptor interacting protein 1 (RIP1) kinase inhibitor and binds to the inactive form of RIP1 in D1-out. For RIP1 and ADP-Glo kinases, IC50 was 16 nM and 10 nM, respectively. |
| M21565 | RIPK1-IN-10 | Ripk1-in-10 is a potent inhibitor of RIPK1. |
| M21564 | RIPK1-IN-7 | Ripk1-in-7 is a receptor interacting protein kinase 1 (RIPK1) inhibitor with Kd value of 4 nM and IC50 value of 11 nM. RIPK1-IN-7 showed good antimetastatic activity in experimental B16 melanoma lung metastasis model. |
| M13555 | GSK-872 hydrochloride | GSK-872 hydrochloride is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
